文献速递关节外科

静脉血栓栓塞史并非全关节置换术患者阿司匹林预防的禁忌证

History of Venous Thromboembolism Is Not a Contraindication to Aspirin Prophylaxis in Patients Undergoing Total Joint Arthroplasty.
PubMed 文献 · J Arthroplasty · 2025-11-03

本研究利用全国数据库纳入2010至2023年有静脉血栓栓塞(VTE)病史的原发性全关节置换术(TJA)患者,将接受非阿司匹林抗凝药者按3:1倾向性评分匹配至接受阿司匹林者。结果显示,全膝关节置换术中阿司匹林组深静脉血栓(DVT)风险相当(OR 0.80;95%CI 0.49-1.31),肺栓塞(PE)风险显著更低(OR 0.33;95%CI 0.12-0.85);全髋关节置换术中DVT风险相当(OR 0.67;95%CI 0.34-1.32),PE风险更低(OR 0.19;95%CI 0.05-0.93)。作者认为阿司匹林可能是此类有VTE史患者合适的预防方法,但需前瞻性研究确认。

要点

  • 有VTE史的原发性TJA患者中,阿司匹林组与非阿司匹林抗凝组DVT风险相当。
  • 全膝关节置换术阿司匹林组PE风险显著更低(OR 0.33;95%CI 0.12-0.85)。
  • 全髋关节置换术阿司匹林组PE风险更低(OR 0.19;95%CI 0.05-0.93)。

核心结论

  • 有VTE病史且无肿瘤史的原发性TJA患者,阿司匹林血栓预防相比其他抗凝药,DVT风险相当、PE风险更低。
  • 作者认为阿司匹林可能是此类有血栓栓塞史患者TJA时合适的VTE预防方法,但需前瞻性研究确认最佳抗凝策略。

研究设计与样本

  • 利用全国数据库识别2010至2023年行原发性TJA且有VTE事件记录的患者。
  • 将接受非阿司匹林药物血栓预防的有VTE史原发性TJA患者,按3:1倾向性评分匹配至接受阿司匹林者,匹配变量包括人口学数据、合并症和术前抗凝使用。
  • 排除有活动性或既往肿瘤史的患者。
  • 纳入匹配的全膝关节置换术患者3132例和全髋关节置换术患者2867例进行分析。

主要发现

  • 全膝关节置换术患者中,阿司匹林组DVT风险相当(OR 0.80;95%CI 0.49-1.31),PE风险显著更低(OR 0.33;95%CI 0.12-0.85)。
  • 全髋关节置换术患者中,阿司匹林组DVT风险相当(OR 0.67;95%CI 0.34-1.32),PE风险更低(OR 0.19;95%CI 0.05-0.93)。

局限性

  • 作者指出需前瞻性研究确认该高危人群中最佳抗凝策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although aspirin has become the prophylactic agent of choice for venous thromboembolism (VTE) prevention in low VTE risk patients undergoing primary total joint arthroplasty (TJA), there remains a paucity of data in the literature on the efficacy of aspirin as a mode of chemoprophylaxis in patients who have previously experienced a VTE episode. The purpose of this study was to determine the efficacy of aspirin versus other anticoagulant medications in primary TJA patients who have a documented history of a prior thromboembolic event. METHODS: This study used a national database to identify patients who underwent primary TJA between 2010 and 2023. Only patients who had a documented history of a VTE event were included. Using demographic data, medical comorbidities, and preoperative anticoagulation use, primary TJA patients who had a history of VTE who received nonaspirin medications for thromboprophylaxis were propensity score-matched on a 3:1 basis to those who received aspirin. Patients who had either an active or previous history of cancer were excluded. A total of 3,132 matched patients undergoing primary total knee arthroplasty and 2,867 matched patients undergoing primary total hip arthroplasty were included in the analysis. RESULTS: Among total knee arthroplasty patients, aspirin use was associated with comparable odds of deep vein thrombosis (DVT) (odds ratio [OR] 0.80; 95% confidence interval [CI], 0.49 to 1.31) and significantly lower odds of pulmonary embolism (PE) (OR 0.33; 95% CI, 0.12 to 0.85). Similarly, in the total hip arthroplasty cohort, aspirin users had comparable odds of DVT (OR 0.67; 95% CI, 0.34 to 1.32) and lower odds of PE (OR 0.19; 95% CI, 0.05 to 0.93). CONCLUSIONS: We found that patients who had a prior VTE episode and no oncologic history receiving aspirin thromboprophylaxis following primary TJA had comparable odds of developing DVT and lower odds of experiencing PE relative to patients receiving other types of anticoagulation. Based on these findings, it appears that aspirin may be a suitable method of VTE prophylaxis in patients undergoing TJA with a prior thromboembolic episode; however, prospective studies are warranted to confirm the optimal anticoagulation strategy in this high-risk cohort.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Verhey JT, Tarabichi S, Brinkman JC, et al. History of Venous Thromboembolism Is Not a Contraindication to Aspirin Prophylaxis in Patients Undergoing Total Joint Arthroplasty. J Arthroplasty. 2025. PMID: 41192530. doi:10.1016/j.arth.2025.10.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。